Focused ultrasound, essentially concentrated sound waves, have been used in early-stage clinical trials to temporarily disrupt the blood-brain barrier, creating a window of time where a therapeutic treatment could be delivered in a targeted manner. The potential impact of this advancement is enormous.
Almost no new therapies have succeeded in extending patient survival in GBM in the last 20 years, and the field is littered with drugs that have failed despite promising early data. But researchers soldier on with new molecular targets and therapeutic modalities.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
"Our philosophy is that it is as important to fail fast as it is to succeed quickly," said Nader Sanai, the director of the Ivy Brain Tumor Center at Barrow Neurological Institute.
The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.
Tempe, Arizona-based GT Medical Technologies has developed the GammaTile, a surgically targeted brachytherapy technology for the treatment of recurrent brain tumors.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Houston-based company is crowdfunding its way to providing new hope for glioblastoma patients.
On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
As many as two-thirds of glioblastoma patients don't respond to a central class of treatments due to a nifty DNA repair mechanism known as MGMT. DelMar Pharmaceuticals has a workaround that it hopes can extend the lives of patients in a meaningful way.
Just this month, the company received orphan drug designation in both the European Union and America for treating glioblastoma.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Immunotherapy is emerging as a powerful tool to treat glioblastoma - an aggressive form of brain cancer. Cambridge startup is developing a CAR-T approach to the disease, and is raising a $20 million Series A to do so.
Celldex's brain cancer vaccine improves survival rates and, importantly, improves quality of life, according to new topline results just released by the company.
Brain tumors are usually treated with an intense course of cancer’s Big Three: Surgery, radiation and heavy chemotherapy. Medical device startup Novocure is adding a new treatment option into the mix: Electrofield therapy, in which alternating electric fields shut down cellular division – curbing the growth of cancer. It’s called Optune. And it seems to be wildly […]
The market for newly diagnosed brain cancer therapies is in serious need of new innovation – few therapies exist on the market for this indication. Diffusion Pharmaceuticals, a 13-year-old Virginia biotech in the midst of mid-stage clinical trials for brain cancer, just raised about $3.5 million, according to a regulatory filing. The company’s most advanced drug […]